Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus – V161
Oncolytic Virotherapy Summit
December 6 – 8, 2022
BIO-Europe
October 24 – 26, 2022
14th International Oncolytic Virotherapy Conference (IOVC 2022)
October 23 – 26, 2022
Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes
Virogin Biotech Receives IND Approval from the U.S. FDA for VG201
Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company is pleased to announce that their Investigational New Drug (IND) application for VG201 has been granted by the U.S. Food and Drug Administration (FDA), allowing Virogin to initiate a Phase I clinical trial of VG201. VG201 is Virogin’s first product candidate built with Transcriptional and Translational […]
Virogin Biotech Receives IND Approvals from Chinese NMPA for VG201 and VG161
Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company, is pleased to announce that, on April 19, 2022, the National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices, granted IND approvals for the company’s investigational drug candidates VG201 and VG161, allowing the initiation of a Phase I clinical trial of […]
